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MeCP2 is a nuclear protein that is mutated in the se-
vere neurological disorder Rett syndrome (RTT). The
ability to target b-galactosidase to the nucleus was
previously used to identify a conserved nuclear local-
ization signal (NLS) in MeCP2 that interacts with the
nuclear import factors KPNA3 and KPNA4. Here,
we report that nuclear localization of MeCP2 does
not depend on its NLS. Instead, our data reveal that
an intact methyl-CpG binding domain (MBD) is suffi-
cient for nuclear localization, suggesting that MeCP2
can be retained in the nucleus by its affinity for DNA.
Consistent with these findings, we demonstrate that
disease progression in a mouse model of RTT is un-
affected by an inactivating mutation in the NLS of
MeCP2. Taken together, our work reveals an unex-
pected redundancy between functional domains of
MeCP2 in targeting this protein to the nucleus,
potentially explaining why NLS-inactivating muta-
tions are rarely associated with disease.INTRODUCTION
Eukaryotic cells are defined by having their genetic material con-
tained within a membrane-bound organelle known as the nu-
cleus. The nuclear pore complex (NPC) is a large protein channel
embedded in the nuclear membrane that mediates transport of
macromolecules between the nucleus and the cytoplasm. Small
proteins are able to diffuse passively through the NPC, whereas
larger factors require a nuclear localization signal (NLS)—a short
motif that binds to proteins mediating active transport through
the NPC (Sorokin et al., 2007). One such factor thought to require
NLS-dependent transport into the nucleus is the chromatin-
associated protein, MeCP2.
MeCP2 has been subjected to intense study since the discov-
ery that mutations in this factor cause Rett syndrome (RTT)—a
severe neurological disorder affecting approximately 1 in
10,000 girls (Amir et al., 1999). The original identification of
MeCP2 was based on the affinity of its methyl-CpG binding
domain (MBD) for DNA containing methylated CpG dinucleo-Cell R
This is an open access article undtides (Lewis et al., 1992; Nan et al., 1993). RTT-causingmissense
mutations cluster within theMBD and impair the ability ofMeCP2
to interact with chromatin (Baubec et al., 2013; Christodoulou
et al., 2003; Goffin et al., 2011), and so MBD-mediated binding
to DNA is likely to be essential for MeCP2 function. Analysis of
brain regions from MeCP2-deficient mice revealed a slight rela-
tive increase in the expression levels of many genes with the
greatest number of methylated cytosines, suggesting that
MeCP2 functions as a weak but global transcriptional repressor
(Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 2017).
Consistent with this view, a second cluster of RTT-causing mu-
tations in MeCP2 destroys its interaction with the NCOR1/
NCOR2 co-repressor complex (Kruusvee et al., 2017; Lyst
et al., 2013). Alternative models of MeCP2 molecular function
have also been proposed, including roles in transcriptional acti-
vation (Chahrour et al., 2008; Li et al., 2013), alternative splicing
(Young et al., 2005), microRNA processing (Cheng et al., 2014),
and chromatin compaction (Baker et al., 2013). Although, the
precise connection between these putative MeCP2 functions
and RTT pathology has yet to be firmly established, each model
nevertheless requires the presence of MeCP2 in the nucleus
(Lyst and Bird, 2015).
In this study, we reveal a redundancy in the mechanism by
which MeCP2 is localized to the nucleus. We report that nuclear
localization of MeCP2 is not exclusively dependent on its canon-
ical NLS. Rather, we find that either an intact NLS or chromatin
binding is sufficient for nuclear retention. Consistent with NLS-
independent nuclear localization of MeCP2, we find that disease
progression in a mouse model of Rett syndrome is not impacted
by a mutation that abolishes binding of the MeCP2 NLS to the
nuclear import factors Kpna3 and Kpna4. Taken together, our re-
sults reveal a functional redundancy between DNA binding and
the NLS in targeting MeCP2 to the nucleus. This may rationalize
the absence of pathogenic mutations in the NLS of MeCP2 and
may also be considered as an explanation for the scarcity of dis-
ease-causing mutations in the NLS motifs of other factors
(McLane and Corbett, 2009).
RESULTS
The NLS of MeCP2 Interacts with KPNA3 and KPNA4
Previously, we affinity purified MeCP2 from the brains ofMecp2-
EGFP knockin mice and identified the nuclear import factorseports 24, 2213–2220, August 28, 2018 ª 2018 The Authors. 2213
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. The NLS of MeCP2 Interacts with
KPNA3 and KPNA4
(A) Schematic of the primary structure of MeCP2
showing the positions of the methyl-CpG binding
domain (MBD), the first AT-hook (hook 1), the nu-
clear localization signal (NLS), and the NCOR1/
NCOR2 interaction domain (NID). The expanded
view of the NLS depicts the two basic patches of
this motif (gray), the overlapping AT-hook 2
(hook 2) (pink), and the positions of the RTT-
causing truncation mutations R255X, R270X, and
G273X (bold). Horizontal black lines indicate the
extent of the deletions used in the MBD and in
AT-hook 1.
(B) Immunoprecipitation (IP) of MeCP2, Kpna3,
and Kpna4 from extracts of wild-type (WT) mouse
brain using an antibody against MeCP2. IP from
Mecp2 knockout (KO) brain is a negative control.
(C) Coomassie stain of purified GST-MeCP2NLS
(GST-NLS) and GST alone.
(D) Western blotting reveals in vitro-translated
33FLAG-tagged Kpna4 is bound byGST-NLS, but
not by GST alone.Kpna3 and Kpna4 as binding partners by mass spectrometry
(Lyst et al., 2013). Subsequently, others mapped the KPNA3/
KPNA4 binding site on MeCP2 to its previously identified NLS
(Baker et al., 2015; Nan et al., 1996). This bipartite NLS is located
between the MBD and the NCOR1/NCOR2 interaction domain
(NID) of MeCP2 (Figure 1A).
To validate the mass spectrometry data and to ensure that
these interactions are not artifacts of the EGFP tag, we per-
formed immunoprecipitation fromwild-typemouse brain nuclear
extracts using an antibody against MeCP2 and revealed bound
Kpna3/Kpna4 by western blotting. These proteins were absent
in control immunoprecipitations performed using extracts from
Mecp2-null mice, demonstrating the specificity of this assay.
MeCP2 binding to Kpna3/Kpna4 was still readily detectable
even using stringent washes with 300 mM sodium chloride, sug-
gesting that this interaction is robust (Figure 1B). Next, we tested
whether the MeCP2 NLS is sufficient to bind directly to the nu-
clear import machinery. To this end, we bacterially expressed
and purified the MeCP2 NLS as a glutathione S-transferase
(GST) fusion and immobilized this protein on glutathione Sephar-
ose (Figure 1C). This protein was able to pull down recombinant
33FLAG-tagged Kpna4 produced by in vitro translation in rabbit
reticulocyte lysate. GST alone, on the other hand, showed no
binding to Kpna4 in this assay (Figure 1D). Together with previ-
ous observations, our data strongly suggest that the MeCP2
NLS interacts directly with the nuclear import machinery in vivo.
TheMBDofMeCP2 Is Sufficient for Nuclear Localization
Previous studies have shown that MeCP2 fused to EGFP local-
izes primarily to the nucleus, even in the presence of truncation
mutations that disturb the originally defined NLS (Baker et al.,
2013, 2015; Kumar et al., 2008; Schmiedeberg et al., 2009).
Possible explanations for these observations could be residual2214 Cell Reports 24, 2213–2220, August 28, 2018activity of the canonical NLS or the presence of an unidentified
NLS in MeCP2, which is not affected by these truncation muta-
tions. An alternative hypothesis—not mutually exclusive with
these models—is that MeCP2 might pass through nuclear pore
complexes in a NLS-independent manner and then be retained
in the nucleus due to its affinity for DNA.
To investigate these scenarios, we introduced a deletion mu-
tation into the MBD—the primary DNA binding domain of
MeCP2. This DNA binding mutant was then combined with trun-
cation mutations, which either preserve or disrupt the NLS. The
resulting proteins were then expressed in NIH 3T3 cells as fu-
sions with EGFP. MeCP2 G273X, which has a wild-type MBD
and preserves the NLS, localized correctly in the nucleus
concentrating at DAPI dense heterochromatic foci (Figure 2A,
upper left). Disrupting the NLS with the R255X mutation had
only a minor effect on this localization, with the protein remaining
overwhelmingly nuclear and concentrated in heterochromatic
foci (Figure 2A, upper right). Nevertheless, analysis of numerous
cells expressing this mutant allowed for the detection of a statis-
tically significant increase in the amount of cytoplasmic EGFP-
MeCP2 (Figure 2B). Deletion of the MBD resulted in the release
of MeCP2 G273X from heterochromatin, but the protein re-
mained predominantly nuclear (Figure 2A, middle left). When,
however, theMBDwasmutated in the context of the R255X trun-
cation, which removes the NLS, MeCP2 was readily detectable
in the cytoplasm (Figure 2A, middle right), indicating that affinity
for DNA might contribute to nuclear localization of MeCP2.
DNA Binding Correlates with NLS Independent Nuclear
Retention of MeCP2
To probe further the relationship between nuclear retention and
affinity for DNA, we extended the deletion mutant in the MBD to
include the adjacent DNA binding motif, AT-hook 1 (Figure 1A).
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Figure 2. Importin Binding Is Not Required
for MeCP2 Retention in the Nucleus
(A) NIH 3T3 cells expressing mutated forms of
MeCP2 as EGFP fusion proteins and counter-
stained with DAPI. The NLS of MeCP2 is intact
(G273X) or truncated (R255X), and the DNA bind-
ing domains areWT, impaired (DMBD), or severely
impaired (DMBDDhook 1). The scale bars repre-
sent 5 mm.
(B) Quantification of ratio of cytoplasmic to nuclear
signal intensity of EGFP-MeCP2 in above panels.
Data points represent individual cells. Horizontal
bars represent means. Statistical significance was
calculated using the Wilcoxon test.
(C) IP using an antibody against EGFP of EGFP-
MeCP2, KPNA3, and KPNA4 from extracts of
HeLa cells expressing full-length (FL), G273X,
R270X, and R255X forms of EGFP-MeCP2.
See also Figure S1.AT-hook 1 is a sequence-specific DNA binding motif that con-
tributes to chromatin binding by MeCP2 (Lyst et al., 2016).
When this deletion was combined with G273X, the NLS of
MeCP2was nevertheless able to direct efficient nuclear localiza-
tion (Figure 2A, bottom left). However, in combination with
R255X, this mutation led to increased cytoplasmic accumulation
of MeCP2 (Figure 2A, bottom right). Notably, in the absence of
the NLS, simultaneous inactivation of the MBD and AT-hook 1
leads to a greater degree of cytoplasmic localization than that
caused by abrogation of the MBD alone (Figure 2B). Therefore,
the data support the conclusion that only inactivation of both
the NLS and the ability to bind to DNA results in substantial cyto-
plasmic accumulation of MeCP2 and that the degree of nuclear
retention correlates well with the ability of NLS-mutated versions
of MeCP2 to bind to DNA (Figure 2B).
ARole forDNABinding in Nuclear Localization ofMeCP2
in Human Neurons
Given that RTT is a neurological disorder, we next askedwhether
this redundancy between the NLS and the DNA binding domains
of MeCP2 could be observed in a more physiologically relevant
neuronal culture system. In particular, we employed the humanCell RepLUHMES cell line, which can be efficiently
differentiated into mature post-mitotic
dopaminergic neurons in vitro (Scholz
et al., 2011). Using a lentiviral expression
system to produce EGFP-MeCP2 in
these cells, we observed that both
MeCP2 G273X and MeCP2 R255X as
well as MeCP2 G273XDMBDDAT-hook
1 were all found in the nucleus as as-
sessed by co-localization with DAPI-
stained DNA (Figure S1, upper three
panels). MeCP2 R255XDMBDDAT-hook
1, on the other hand, the only mutant pro-
tein with the DNA binding domains of
MeCP2 inactivated together with its
NLS, showed minimal co-localizationwith DAPI-stain nuclear DNA (Figure S1, bottom panels). Strik-
ingly, the majority of the EGFP signal was found in aggregates
outside of the nucleus, suggesting that, in this system, the
DNA binding domains of MeCP2 play a key role in directing
NLS-independent nuclear localization of MeCP2. We therefore
conclude that the redundancy between the NLS and the DNA
binding domains of MeCP2, which we first observed in mouse
fibroblasts, is a general phenomenon that also holds true in
human neurons.
MeCP2 R270X Retains a Residual Interaction with
KPNA3/KPNA4
A previous study reported that the R270X mutation in MeCP2
abolishes its binding to KPNA3 but preserves a residual interac-
tion with KPNA4 (Baker et al., 2015). The authors proposed that
this weak binding to KPNA4 was likely to explain the nuclear
localization of MeCP2 R270X. In our hands, as assessed by
co-immunoprecipitation with exogenously expressed EGFP-
MeCP2 in HeLa cells, both KPNA3 and KPNA4 show strongly
reduced binding to the R270X mutation. However, both still
retain a residual interaction compared with the more severe
R255X truncation, which does not bind detectably to KPNA3 ororts 24, 2213–2220, August 28, 2018 2215
KPNA4 (Figure 2C). Given that an intact MBD is able to direct
nuclear targeting of MeCP2 R255X, this weak binding of
MeCP2 R270X to KPNA3/KPNA4 is unlikely to be necessary
for the nuclear localization of this mutant protein. Overall, there-
fore, we conclude that MeCP2 is able to enter the nucleus in an
importin-independent manner and that it can then be partitioned
there due to binding to chromosomal DNA.
NLS Inactivation Does Not Influence MeCP2 Level or
Localization in Mice
An earlier study found that theMeCP2 R270Xmutation gives rise
to more severe neurological deficits than the MeCP2 G273Xmu-
tation in mice. These phenotypic differences were attributed to
the presence of an AT-hook in this region of the protein (AT-hook
2; Figure 1A) rather than any effects of the overlapping NLS, due
to the nuclear localization of MeCP2 R270X (Baker et al., 2013).
However, despite proper nuclear localization of MeCP2 R270X,
loss of a non-canonical function of importin interaction contrib-
uting to the phenotypic deficits in these animals could not be
excluded.
To assess the functional relevance of the MeCP2 NLS, we
generated mutant mice designed to distinguish the effect of
AT-hook 2 from that of importin binding. The first animal model
carried a truncation mutation of MeCP2, where every amino
acid from G273 is removed and replaced with a linker followed
by EGFP. This essentially recapitulates an earlier model (Baker
et al., 2013), except that the mutation is knocked into the endog-
enous locus rather than being expressed as a transgene. A
second linewas constructed similarly, except that four basic res-
idues in the N-terminal part of the NLS were mutated to alanine.
These residues do not overlapwith AT-hook 2 (Figure 1A), and so
this mutation allowed us to separate the phenotypic conse-
quences of inactivating the NLS or this AT-hook (Figure 1A).
We designated these two lines as Mecp2G273X-EGFP and
Mecp2G273XDNLS-EGFP.
We first checked the expression levels of MeCP2 in these
mice. As assessed by western blotting, total MeCP2 was slightly
increased above that in wild-type controls, closely mirroring the
situationwhen full-lengthMeCP2 is taggedwith EGFP (Figure 3A;
Brown et al., 2016). To confirm that the MeCP2G273XDNLS-EGFP
mutation abolished the interaction of MeCP2with Kpna3/Kpna4,
we performed immunoprecipitation using an antibody against
EGFP followed by western blotting with antibodies against
KPNA3 and KPNA4. Whereas Kpna3 and Kpna4 bind robustly
to MeCP2G273X-EGFP, no interaction could be detected with
MeCP2G273XDNLS-EGFP, even though mild buffers containing
only 150 mM sodium chloride were used (Figure 3B).
Next, we investigated the subcellular localization of
MeCP2G273X-EGFP and MeCP2G273XDNLS-EGFP. Imaging of
EGFP in CA1 hippocampal neurons in brain sections from these
mice revealed that both mutant proteins localize correctly to
DAPI dense foci, demonstrating that the NLS is not necessary
for proper nuclear localization of MeCP2 in vivo (Figure 3C). To
confirm the exclusively nuclear localization of these proteins,
we prepared whole-cell and cytoplasmic extracts from these
brains. Western blotting revealed that, unlike the control protein,
gamma-tubulin, MeCP2 was found only in the whole-cell extract
and was completely absent from the cytoplasmic fractions (Fig-2216 Cell Reports 24, 2213–2220, August 28, 2018ure 3D). From these observations, we conclude that, in the brain,
MeCP2G273X-EGFP remains strictly nuclear, evenwhen the inter-
action of its NLS with Kpna3/Kpna4 is lost. The dispensability of
the MeCP2 NLS that we have uncovered in tissue culture
systems therefore appears to be also applicable in the most
physiologically relevant tissue for this protein—the brain.
MeCP2NLS InactivationDoesNot Influence theRTT-like
Phenotype in Mice
As the Mecp2G273X-EGFP and Mecp2G273XDNLS-EGFP mice ex-
press MeCP2 to similar levels, we used these animals to assess
the phenotypic consequences of destroying the interaction of
MeCP2 with Kpna3/Kpna4. Like other RTT models, both lines
initially developed grossly normally before succumbing to
various neurological deficits. In order to make an objective com-
parison of the phenotypic severity in these two lines, we moni-
tored the survival times and body weights of cohorts of male
mice hemizygous for theMecp2 gene. Consistent with the previ-
ous report on the G273X mutation, our Mecp2G273X-EGFP line
displayed a median survival time of 36 weeks (Baker et al.,
2013). This is substantially longer than the median survival time
of 8 weeks reported for Mecp2-null mice (Baker et al., 2013;
Chen et al., 2001; Guy et al., 2001). Our Mecp2G273XDNLS-
EGFPmice also survived longer than null animals with a median
age at death of 41 weeks. This is comparable to survival of the
Mecp2G273X-EGFP animals, with no statistically significant dif-
ference detected between the two groups (Figure 4A). Also
consistent with previous findings on Mecp2-null mice (Guy
et al., 2001), we observed that animals from both lines were un-
derweight when compared to wild-type controls (Figure S2A).
However, in keeping with the similar survival curves of
Mecp2G273X-EGFP and Mecp2G273XDNLS-EGFP mice, we did
not detect a significant difference between the body weights of
these two lines (Figure S2B).
To further characterize the Mecp2G273X-EGFP and
Mecp2G273XDNLS-EGFP mice, we employed a phenotypic
scoring systemdesigned to assay several characteristic features
of the RTT-like phenotype, including activity, gait, hind limb
clasping, tremor, breathing, and general condition (Guy et al.,
2007). Both models initially displayed a rapid onset of symptoms
before remaining relatively stable from approximately 15 weeks.
Strikingly, the trajectory of disease progression was extremely
similar for both lines (Figure 4B), and we were unable to detect
any statistically significant difference between the two groups
at age 15 weeks—the last time point at which all animals were
still alive (Figure S2C).
Finally, we investigated the molecular and histological pheno-
types present in our mutant mice. To this end, we analyzed the
expression levels of a panel of genes previously reported to be
consistently downregulated (Sst,Gabbr1, and Tspan17) or upre-
gulated (Flrt3 and Arhgap10) across multiple brain regions and in
several mouse models of RTT (Baker et al., 2013; Ben-Shachar
et al., 2009; Melle´n et al., 2012; Zhao et al., 2013). When
compared to wild-type controls, both of our mouse lines showed
subtle but statistically significant changes in the expression
levels of these genes. However, for no tested genes were
we able to detect any gene expression changes between
our Mecp2G273X-EGFP and Mecp2G273XDNLS-EGFP animals
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Figure 3. NLS Mutation Does Not Affect the Expression Level or Localization of MeCP2G273X-EGFP in Mouse Brain
(A) Western blotting and quantification of MeCP2 levels in WT, Mecp2-EGFP (EGFP), Mecp2G273X-EGFP (G273X), and Mecp2G273XDNLS-EGFP (NLS) whole-
mouse brain extracts (n = 4). Loading control is anti-histone H3. Quantification is presented as means ± SD.
(B) IP of MeCP2-EGFP from extracts of brains from animals as in (A) using an antibody against EGFP. MeCP2 as well as bound Kpna3 and Kpna4 are detected by
western blotting.
(C) Fluorescence microscopy of MeCP2-EGFP in CA1 layer of hippocampus in brain sections ofMecp2G273X-EGFP (G273X), andMecp2G273GXDNLS-EGFP (NLS)
mice. The scale bars represent 10 mm.
(D) Western blot of MeCP2 levels in cytoplasmic (C) and whole-cell (W) fraction from WT, Mecp2-EGFP (EGFP), Mecp2G273X-EGFP (G273X), and
Mecp2G273GXDNLS-EGFP (NLS) mouse brain. Control cytoplasmic protein is gamma-tubulin.(Figure 4C). To assess the histological phenotypes of ourMecp2
mutant mouse lines, we examined the brain weights and cortical
thicknesses of these animals. Mouse models of RTT have previ-
ously been shown to have smaller brains with reduced cortical
thicknesses (Chen et al., 2001; Robinson et al., 2012). Consistent
with these reports, we found that both the Mecp2G273X-EGFP
and Mecp2G273XDNLS-EGFP animals displayed reduced brain
weights and reduced thickness of the primary motor cortex
when compared to wild-type controls. However, we were unable
to detect any changes in these features when we compared the
two mutant lines with one another (Figures 4D and 4E).
In summary, by monitoring survival, weight, phenotypic
severity score, gene expression profiles, and cortical thickness,
we were not able to observe any additional deficits in
Mecp2G273XDNLS-EGFP mice compared with Mecp2G273X-
EGFP controls. We conclude that importin binding does not sub-stantially affect the course of the pathology in these models of
RTT and that the NLS of MeCP2 does not therefore strongly
contribute to the function of this protein.
DISCUSSION
MeCP2 is a nuclear factor whose ability to recruit the NCOR1/
NCOR2 co-repressor complex to chromatin is essential for
proper brain function. Given that MeCP2 resides in the nucleus,
the absence of disease-causing mutations in its NLS may at first
appear inconsistent with the fact that MeCP2 inactivation leads
to Rett syndrome. We have resolved this paradox by uncovering
a functional redundancy in the mechanism by which MeCP2 is
targeted to the nuclear compartment. An alternative explanation
for the lack of RTT-causing mutations in the NLS would be if
spontaneous mutations inactivating the MeCP2 NLS do notCell Reports 24, 2213–2220, August 28, 2018 2217
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Figure 4. MeCP2G273X-EGFP Mice Appear
Unaffected by a Mutation Inactivating the
MeCP2 NLS
(A) Survival curves forMecp2G273X-EGFP (n = 8) and
Mecp2G273XDNLS-EGFPmice (n = 9), aswell aswild-
type controls for each group (n = 12 and n = 10,
respectively). No significant difference
between survival of Mecp2G273X-EGFP and
Mecp2G273XDNLS-EGFP mice was observed
(p = 0.78; Kolmogorov-Smirnov test). An illustrative
survival curve for Mecp2-null mice (based on data
from previous studies) is shown as a broken line.
(B) Average phenotypic severity score of surviving
animals plotted against age for each of the
groups. Data for each group are plotted up to the
last point, where there are at least three surviving
animals.
(C) Expression levels relative to Gapdh of genes
that are upregulated (Flrt3 and Arhgap10) or
downregulated (Sst, Tspan17, and Gabbr1) in
brains of Mecp2 mutant mice as assessed by
qPCR. Data are presented as means ± SD.
(D) Brain weights for Mecp2G273X-EGFP and
Mecp2G273XDNLS-EGFP mice (n = 4 for each
group) as well as wild-type controls (n = 5 and
n = 3). Indicated statistical significance was
calculated using the t test. Data are presented as
means ± SD.
(E) Cortical thickness plotted for Mecp2G273X-
EGFP and Mecp2G273XDNLS-EGFP mice (n = 4
each) and wild-type control animals (n = 5 and
n = 3). Data are presented as means ± SD. Indi-
cated statistical significance was calculated using
the t test. The image depicts the area of the pri-
mary motor cortex (M1) measured. The scale bar
represents 1,000 mm.
See also Figure S2.occur in the human population. However, this appears unlikely,
given the demonstration that a single amino acid substitution
in the NLS can abolish its interaction with the nuclear import ma-
chinery (Baker et al., 2015).
The NLS of MeCP2 was originally defined by expressing frag-
ments of MeCP2 as beta-galactosidase fusion proteins and as-
saying their localization in mouse fibroblasts (Nan et al., 1996). In
this system, the NLS was necessary for MeCP2 to be partitioned
in the nucleus. At first sight, these data contradict our finding that
theMeCP2NLS is dispensable for its nuclear localization. A likely
explanation for the discrepancy is that beta-galactosidase, a
large 464-kDa homo-tetramer, fused to MeCP2 might obligato-
rily require active transport through the nuclear pore complex.
According to this hypothesis, smaller MeCP2 fusions with
EGFP would be capable of NLS-independent entry into the nu-
cleus, where they are then retained by their affinity for DNA.
Although we cannot formally exclude the possibility that the
DNA binding domains of MeCP2 interact with the nuclear import2218 Cell Reports 24, 2213–2220, August 28, 2018machinery to mediate active transport of
this protein into the nucleus, we consider
this less likely. First, we find no evidence
for these domains interacting with the
nuclear import machinery (Figure 2C).Second, two independent DNA binding domains, the MBD and
AT-hook 1, act synergistically to direct nuclear localization.
These two domains are structurally unrelated, but each has an
affinity for a subset of nucleotide sequence motifs that is
frequent in the genome.
Given that the MeCP2 NLS appears not to be required for
localization of MeCP2 in the nucleus, a question arises as to
the function of its interaction with KPNA3 and KPNA4. The
NLS is a highly conserved region of MeCP2, and so its inactiva-
tion is likely to be detrimental, even if only on evolutionary time-
scales. One possibility is that importin binding to MeCP2 reflects
a non-canonical role of these proteins. Importins have been pro-
posed to function as chaperones for certain factors (Ja¨kel et al.,
2002), and KPNA3/KPNA4 binding to MeCP2 could also reflect
such a role. Alternatively, the selection pressure on the MeCP2
NLS may arise due to an extremely subtle effect on the
nuclear targeting of this protein. For example, the kinetics of
MeCP2 nuclear import might be perturbed or an extremely low
concentration of MeCP2 in the cytoplasm of large neurons might
reduce the amount of active protein available in the nucleus.
Whatever the role of MeCP2 binding to the nuclear import ma-
chinery, our work has highlighted the importance of using ge-
netics to avoid misattributing disease relevance to evolutionarily
conserved biochemical interactions.
This study has uncovered a surprising redundancy between the
DNA binding domains and the NLS ofMeCP2 in the nuclear local-
ization of this factor. Given the paucity of NLS-inactivating muta-
tions implicated in other genetic disorders (McLane and Corbett,
2009), an interesting line of future work will be to determine
whether chromatin binding also contributes to nuclear sequestra-
tion of other factors. As well as providing insights into the mecha-
nismof nuclear targeting ofMeCP2, the present study should also
be of interest to researchers seeking treatments for Rett syn-
drome. Currently, the gene therapy vectors showing the most
promise in targeting theCNShavea limitedcapacity, leading toef-
forts to miniaturize MeCP2 expression constructs containing only
the required functional domains (Tillotson et al., 2017). By better
delineating the disease-relevant functional domains of MeCP2,
our work has both improvedmolecular understanding of this pro-
tein and also strengthened the groundwork for one of the more
promising strategies for treating Rett syndrome.
EXPERIMENTAL PROCEDURES
Protein Interactions
Co-immunoprecipitation and in vitro binding assays were performed essen-
tially as described previously (Lyst et al., 2013), except that buffers were sup-
plemented with 300 mM rather than 150 mM sodium chloride where indicated.
GST fusion proteins were produced as described elsewhere (Lyst et al., 2016).
Cell Imaging
NIH 3T3 cells were maintained, transfected, harvested, fixed, and imaged as
described previously (Lyst et al., 2013). LUHMES cells were maintained and
transduced with lentiviruses as described previously (Shah et al., 2016). Im-
ages were quantified using the ImageJ software package with the investigator
blind to the identities of the transfected MeCP2 constructs. DMBD and
DMBDDAT-hook 1 constructs lacked amino acids 111–168 and 111–191.
Subcellular Fractionation
For preparation of whole brain and cytoplasmic brain extracts, fresh material
(not frozen) was dounce homogenized in NE1 buffer (20 mM HEPES
[pH 7.5], 10 mMNaCl, 1 mMMgCl2, and 0.1% Triton X-100). This homogenate
was taken as whole-brain extract, and the supernatant following centrifugation
for 5 min at 500 g was taken as cytoplasmic extract.
Animals
All animal experiments were carried out by staff licensed by the UK Home
Office in accordance with the Animal and Scientific Procedures Act 1986. Tar-
geting vectors for generating mutant mice were based on one described else-
where (Lyst et al., 2013). For the NLS mutation, four consecutive amino acids
(RKRK) comprising the N-terminal basic cluster of this bipartite signal were
mutated to alanine. Targeting vector was co-transfected into 129/Ola E14
TG2a mouse embryonic stem cells (ESCs) with Cas9 (nicking) and appropriate
guide RNA expression plasmids (Ran et al., 2013). Mice were generated from
these cells by standard procedures before backcrossing onto the C57BL/6
background for at least two generations. Scoring of phenotypes was per-
formed blind to genotypes as described elsewhere (Guy et al., 2007), with
wild-type and mutant male mice being weighed and monitored weekly from
4 weeks of age for one year. For biochemical analysis (co-immunoprecipita-
tion, subcellular fractionation, and western blotting), brains were taken from
male mice aged 8–18 weeks.Histology
Brains from wild-type and mutant male littermates aged 10–18 weeks were
dissected, removing the olfactory bulb and trimming to remove any spinal
cord. Brains were weighed and immersed in fixative (3.7% paraformaldehyde
in PBS). After 2 hr, brains were transferred to fresh fixative and stored overnight
at 4C. Brains were transferred to 30% sucrose solution in PBS and stored at
4C for 48 hr, replacing the solution after 24 hr. Brains were then frozen in iso-
pentane, chilled on dry ice, and stored at80C. A Leica CM1900 cryostat set
to 26C was used to cut 30-mm coronal sections, which were mounted on
SuperFrost Plus slides and dried. Sections were photographed using an
Olympus SZX10 microscope at 2.63magnification. The location of each sec-
tion was determined with reference to ‘‘The Mouse Brain in Stereotaxic Coor-
dinates’’ (Franklin and Paxinos, 2008). The primary motor cortex was defined
using the atlas and the cortical thickness measured near to the center of the
region. Between 22 and 33 sections were measured for each mouse, between
0.98 and 0.46 mm from Bregma (Franklin and Paxinos, 2008).
Gene Expression Analysis
Total RNA was purified from whole brains of male mice aged 7–14 weeks
using TRI Reagent (Sigma; T9424). The QuantiTect Reverse Transcription Kit
(QIAGEN) was used for cDNA synthesis, and gene expression was quantified
using the SensiMix SYBR & Fluorescein kit (Bioline) on a LightCycler 480.
Statistical Methods
For quantification of the nuclear to cytoplasmic ratio of EGFP-MeCP2mutants
in NIH 3T3 cells, statistical significancewas calculated using theWilcoxon test.
For qPCR data as well as analysis of brain weights and cortical thicknesses,
p values were calculated using the Student’s t test. The Kolmogorov-Smirnov
test was used to calculate p values for comparisons of body weights and
phenotypic scores.
Antibodies
Antibodies usedwere as follows: Histone H3 (Abcam; ab1791); gamma-tubulin
(Sigma; T5326); MeCP2 (Sigma; M6818 and M7443); KPNA3 (Abcam;
ab6038); KPNA4 (Bethyl Laboratories; A301-627A); EGFP (CRUK and Chro-
motek gta-10); and FLAG (Sigma; F3165).
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